Environment
Mixed / Neutral
50%
Benefits
- No direct environmental benefit identified
Risks
- No direct environmental risk identified
FederalUS CongressIntroduced
H.R. 1266: Combating Illicit Xylazine Act
Rep. Jimmy Panetta (D-CA)
H.R. 1266 status: Introduced.
01
What this bill does
Official summary alongside an AI-generated read on where it stands and why.
Overall Score
50OUT OF 100
Score:50/100 civic fit
Risk:Low Risk
Impact:Low Impact
Earlier scoring method. Reanalyze to use the sector calculation.
Constitutionality70%
Bipartisan80%
Public opinion60%
Bill summary
No official summary is available for this bill.
02
Impact analysis
✦ AI analysisModeled effects across six domains, estimated from bill text and comparable legislation.
Economy
Mixed / Neutral
50%
Benefits
- Facilitates and expedites manufacturer submissions for xylazine.
Risks
- Entities manufacturing xylazine are exempt from certain security standard capital expenditures.
Society
Positive outlook
60%
Benefits
- Adds xylazine to Schedule III of the Controlled Substances Act, increasing regulatory control.
- Clarifies 'ultimate user' definition for xylazine to include specific animal-related and government uses.
- Requires review and potential amendment of sentencing guidelines for xylazine offenses.
Risks
- Delays full implementation of Schedule III labeling, packaging, and distribution requirements for xylazine by one year.
- Delays full implementation of Schedule III practitioner registration, inventory, and recordkeeping for xylazine by 60 days.
Technology Industry
Not scored in this analysis.
Generate analysis again to evaluate this sector.
Civic Accountability
Not scored in this analysis.
Generate analysis again to evaluate this sector.
Public Health & Safety
Not scored in this analysis.
Generate analysis again to evaluate this sector.
03
How trustworthy & consequential it is
Sourcing already shown above, this is what the analysis found worth flagging.
Confidence
High
Information is complete and verified.
Analysis basis
Full bill text (Congress.gov)
Source used for this bill's analysis.
Warning
The full impact depends on the effectiveness of the DEA and FDA in facilitating manufacturer submissions.
Analysis scope
The bill does not prohibit all uses of xylazine, only certain illicit uses.
04
Where it stands
Official record- IntroducedCurrent
- CommitteeUpcoming
- House and SenateUpcoming
- Final agreementUpcoming
- PresidentUpcoming
- EnactedUpcoming
05
How it affects your district
✦ Personalized
Set your location
Add your district to see how this bill may affect your community and who to contact.
Your Representatives
Your representatives appear here once you add your location.
06
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.